Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

Abstract

Michigan. He then completed a clinical pharmacy residency at the University Hospital of the University of Michigan. Bartels is a board-certified pharmacotherapy specialist and a certified diabetes educator.At Bartels' s clinical practice at the University Primary Care Clinic at Belvidere, which is a primary care training site operated by the University of Illinois College of Medicine at Rockford, he is responsible for providing diabetic education to patients; teaching medical, pharmacy, and nurse practitioner students in the clinic setting; and conducting clinical research with investigational antidiabetic medications.Bartels also provides didactic lectures on the pharmacology and therapeutics of cardiovascular and antidiabetic agents for medical and pharmacy students from the University of Illinois. He has given numerous invited presentations on diabetes management to pharmacists, physicians, and certified diabetes educators, and he has been involved in writing and publishing several key papers on diabetes and its management in pharmacy journals and other professional publications. As a faculty member, Gong is responsible for teaching in the primary care clerkships and providing lectures in the therapeutics series. He is actively involved with professional organizations, having served as vice chair and chair for the Primary Care Specialty Practice Group of ASHP, as an executive board member of the ASHP Section of Clinical Specialists, and on the ASHP Commission on Credentialing. He has published and given numerous presentations on ambulatory care pharmacy practice issues and diabetes care on the national and local levels. Gong is cited in the Congressional Record for pharmacy practice achievements, is a fellow of ASHP, and a fellow of the California Society of Health-System Pharmacists. Michael F A C U L T Y Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to assure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results.1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. 5. Seek and publish content that does not duplicate content in the Journal of Managed Care Pharmacy. 6. Subject all supplements to expert peer review. Target AudiencePharmacists and physicians managing diabetic and pred...

Metabolic effects of 20-OH-Ecdysone in ovariectomized rats

“…E2 is known to prevent fat tissue accumulation and to reduce serum cholesterol levels in many castrated mammals and in postmenopausal women [3,4,20]. This was confirmed in the present study to occur also in ovx rats.…”

“…Chronic obesity reaches epidemic dimensions and may result in the metabolic syndrome of which the end stage is type II diabetes, hypertension and arteriosclerosis with all consequent following diseases such as heart attacks and strokes [1][2][3][4]. According to WHO 1 billion people are overweight in the world.…”

Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus

“…The rising incidence of T2DM has resulted in CVD becoming the leading cause of morbidity and mortality worldwide (1). This increased risk of CVD is due to a complex cluster of risk factors associated with T2DM including insulin resistance, hyperglycemia, diabetic dyslipidemia, hypertension, hyperinsulinemia, systemic inflammation and adipose tissue-derived factors (2).…”

Clinical Significance of Procalcitonin and C-Reactive Protein in the Prediction of Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus

“…This is due to a complex group of risk factors associated with T2DM including insulin resistance, hyperglycemia, diabetic dyslipidemia, hypertension, hyperinsulinemia, systemic inflammation, and adipose tissue-derived factors [4][5][6]. Worth mentioning, the changes in the mass and metabolism of adipose tissue may be paralleled by insulin resistance and visceral obesity commonly associated with T2DM [7].…”